Early Experience With Eravacycline for Complicated Infections
Early Experience With Eravacycline for Complicated Infections
复制标题
DOI：
10.1093/ofid/ofaa071
复制
发表时间：
2020-05-01
影响因子：
4.2
通讯作者：
Rybak, Michael J.
中科院分区：
文献类型：
--
作者：
Alosaimy, Sara;Molina, Kyle C.;Rybak, Michael J.
埃拉环素（ERV）用于35例各种感染患者。最常见的病原体是肺炎克雷伯菌，30天存活率为74%。无30天复发和感染体征和症状的解决分别为91%和57%。ERV耐受性良好，1例患者发生不良事件导致停药。
Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.